



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

GeneGo is awarded NIEHS grant in toxicogenomics

St. Joseph, Michigan, May 24th, 2005 – GeneGo, Inc., a leading provider of databases, software and services in systems biology, announced today they have received a Phase I SBIR grant from the National Institute of Environmental Health Sciences for the elucidation and analysis of signaling and metabolic networks implicated in cellular response to drugs and toxins. In the first phase of research, publicly available data will be re-analyzed by GeneGo scientists using the company's flagship systems biology platform, MetaCore™.

“Over the past few years, we have witnessed an unprecedented accumulation of gene expression and other high throughput data in toxicity research”, said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo. “This has been mainly rat and mouse microarray data that has been interrogated with then currently available tools, but some important biological mechanisms and patterns were missed, as they can be only accessed via analysis of biological networks. Now we intend to re-examine the data from different microarray platforms and identify specific modules, “signature networks”, characteristic for toxic effects and conserved cross-platform”.

"MetaCore gene network analysis will address a critical need in drug safety evaluation by the identification of novel diagnostic biomarkers for adverse responses to drugs or chemicals”, said Professor Craig Giroux from Wayne State University, a consultant on the grant. “In addition, these unique Gene Network Signature motifs will provide a valuable resource in support of biomarker development programs for comparative toxicogenomics and predictive risk assessment of environmentally responsive disease in my and other labs.”

About GeneGo

GeneGo is a Michigan-based company developing systems biology technology for life science research. The Company's original computational platform allows an integration and analysis of different kinds of experimental data (mRNA expression, proteomics, metabolites, phenotypic data etc.) and relevant active chemistry (metabolites, drugs, other xenobiotics) within the framework of biological pathways and networks. GeneGo's first

product, MetaCore™, assists scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. GeneGo's second product, MetaDrug™, is designed for medicinal chemists and enables prediction of metabolites and their likely toxicity in human. For more information, please visit the company's Web site at www.genego.com.

For more information, please visit the company's Web site at www.genego.com .

MetaCore™, MetaDrug™ and MetaBase™ are trademarks of GeneGo, Inc